|
| 15例非胃黏膜相关淋巴组织淋巴瘤临床特点与疗效分析 |
| Analys is of clinical features and outcomes of 15 cases of non-gastric MALT lymphoma |
| 投稿时间：2015-11-15 |
| DOI：10.3969/j.issn.1000-0399.2016.02.007 |
| 中文关键词: 黏膜相关淋巴组织 淋巴瘤 利妥昔单抗 |
| 英文关键词: Mucosa-associated lymphoid tissue Lymphoma Rituximab |
| 基金项目: |
|
| 摘要点击次数: 1669 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨非胃黏膜相关淋巴组织(MALT)淋巴瘤的临床特点和治疗方法。方法 回顾性分析安徽省肿瘤医院2011年6月至2015年6月收治的15例非胃MALT淋巴瘤患者临床资料。结果 在一线接受放疗或(和)化疗的15例患者中,总有效率为100.00%。局限期(Ⅰ~Ⅱ期)患者完全缓解率明显高于进展期(Ⅲ~Ⅳ期)患者(P<0.05),原发部位在头颈部患者总生存(OS)率、无疾病进展生存(PFS)率优于原发于肺及小肠患者(P<0.05)。14例化疗患者中,使用利妥昔单抗患者的OS率、PFS率与未使用患者相比,无明显优势。局限期患者OS率、PFS率优于进展期患者,但差异无统计学意义。结论 非胃MALT淋巴瘤疾病进展缓慢,预后良好,临床上可根据患者病变范围和身体状况选择适当治疗。 |
| 英文摘要: |
| Objective To study the clinicalfeatures and treatment ofthe non-gastric mucosa-associated lymphoid tissue(MALT) lymphoma.Methods The clinical data of 15 patients with non-gastric MALT lymphoma, ever treated in our hospitalfrom Jun 2011 to Jun 2015, were retrospectively analyzed.Results The total effectiveness rate was 100% in these15 patients receivingfirst-lineradiotherapy and chemotherapy.The limited stage(stage I~Ⅱ) patients had a significantlyhighercomplete remission rate than thoseprogressive stage(stage Ⅲ~IV) patients(P<0.05).There weresignificantlybetteroverall survival(OS) rate and progression-free survival(PFS) rateinpatients with primary lesionsin the head and neckthan those withprimary lesions in the lung and small intestine(P<0.05).Among 14 cases with chemotherapy, patientsreceiving rituximab treatmentexhibited no significant advantage in the OS and PFSrates in comparison with those without.The limited stage(stage I~Ⅱ) patients had better OS and PFS ratesthan those progressive stage(stage Ⅲ~IV) patients, but with no significant differences.Conclusion The progressof non-gastric MALT lymphoma is relatively slow with agood prognosis.The appropriate clinical therapiesshould bedecidedaccording to the lesion area and physical conditionof patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
